priors.science/reviews/obesity-pharmacotherapy

Obesity Pharmacotherapy

The current evidence on 7 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

7claims tracked

101primary papers reviewed

2 Jun 2026latest evidence review

Weeklyre-scored against new papers

7 Established · 0 Likely · 0 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableSema 2.4 mg ~15% weight lossSema WLEstablished93%—

StableTirzepatide 15 mg ~21% weight lossTirz WLEstablished93%—

StableSema 2.4 mg >50% achieve ≥15%Sema WLEstablished91%—

StableSema 2.4 mg sustained on-treatmentSema WLEstablished90%—

StableTirzepatide ≥20% in one-thirdTirz WLEstablished90%—

StableSema 2.4 mg adolescent obesitySema WLEstablished88%—

StableLiraglutide 3 mg 5–8% weight lossSema WLEstablished88%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic